SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-19-313342
Filing Date
2019-12-13
Accepted
2019-12-13 06:31:11
Documents
12
Period of Report
2019-12-13
Items
Item 7.01: Regulation FD Disclosure

Document Format Files

Seq Description Document Type Size
1 8-K d553702d8k.htm   iXBRL 8-K 23294
  Complete submission text file 0001193125-19-313342.txt   145286

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA aeri-20191213.xsd EX-101.SCH 3080
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE aeri-20191213_lab.xml EX-101.LAB 18140
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE aeri-20191213_pre.xml EX-101.PRE 11415
8 EXTRACTED XBRL INSTANCE DOCUMENT d553702d8k_htm.xml XML 3420
Mailing Address 4301 EMPEROR BOULEVARD SUITE 400 DURHAM NC 27703
Business Address 4301 EMPEROR BOULEVARD SUITE 400 DURHAM NC 27703 (919) 237-5300
AERIE PHARMACEUTICALS INC (Filer) CIK: 0001337553 (see all company filings)

IRS No.: 203109565 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36152 | Film No.: 191283348
SIC: 2836 Biological Products, (No Diagnostic Substances)